Ann: Opthea Appoints John Han, PharmD, as VP Medical Affairs, page-5

The last paragraph sounds like Opthea have set their media statements in stone. In particular, making sure that comments must include "first product in 15 years....superior and meaningful visual outcomes..." and they're also reminding the market of the "mid 2025 top line results" whenever they can, whilst reminding investors that Sozinibercept is a product candidate. Bit like applying for a job really.

Nothing wrong with that, but another high level appointment means even more cash burn. With over 660 million shares outstanding, I hope that we don't see further dilution in the future. But for sure the hat will get passed around again closer to the conclusion or thereabouts of the P3 trial(s). I suspect that by that point, the speculation will carry the share price further north by a considerable margin and some participants on this forum will have made for themselves a tidy sum.